Full Agonist Vs Partial Agonist

Mohamad Ali Salloum, PharmD • April 24, 2022

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button

As discussed in previous article, an agonist is a molecule that causes a physiologic response when it binds to its receptor.


A drug can be classified as Full agonist or Partial agonist depending on its efficacy.


Let’s Say Drug A is the Full agonist and Drug B is the partial agonist.


So, how both can be agonists and have different magnitude of action?


A full agonist can be effective 100% although not all receptors are occupied. This means that Drug A needs less than 100% of the receptors to result in full response.


On the other hand, drug B, a partial agonist will never be able to reach 100% even if it occupied 100% of the receptors present.


This happens because the physico-chemical properties of the full agonist that allow it to make a bond with the receptor in a way that it can excite only 3 receptors (theoretically) to result in 100% of the effect.


The physico-chemical properties of the partial agonist allow it to bind to its receptor, however, with lower ability to excite it and produce the desired response, even with occupying 100% of the receptors present.


Examples of full agonists are morphine, opium and phenylephrine. Buprenorphine and Tolazoline are examples of a partial agonist.

You can also watch the illustrative video below for more understanding of the topic.


Resources:


 1)      R. J. F. R. H. G. Rang HP, Rang and Dale's pharmacology, ed., vol. , , : Elsevier


List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD April 11, 2026
    How modern psychotherapy, neurosciencebased interventions, and personalized medicine are reshaping addiction treatment
    By Mohamad-Ali Salloum April 8, 2026
    How substance use progresses from experimentation to compulsive addiction.
    By Mohamad-Ali Salloum, PharmD April 6, 2026
    How emotional dysregulation, traumatic experiences, and chronic stress shape vulnerability to addiction.
    By Mohamad-Ali Salloum, PharmD April 5, 2026
    References: Biological Psychiatry Study. HDAC5 limits expression of Scn4b and regulates drug memory formation and relapse. ScienceDaily. 2025. 1 Fang Y, Sun Y, Liu Y, et al. Neurobiological mechanisms and clinical treatment of addiction. Psychoradiology. 2022;2(4):180189. 2 Palombo P. Neurobiology of Substance Use Disorders. Springer; 2025. 3 
    By Mohamad-Ali Salloum, PharmD April 3, 2026
    How scientific models explain the roots and progression of addictive behavior
    By Mohamad-Ali Salloum, PharmD April 1, 2026
    References: Karimpourvazifehkhorani A, Hekmati I. Habit loop in addictive behaviors formation among adolescents: The mediating role of impulsivity. Curr Psychol. 2025;44:4313–4325. Simón Márquez MM, Fernández Gea S, Molero Jurado MM, et al. Addictions and risk behaviors in adolescence: A systematic review. Front Psychol. 2025;16. Legends Recovery. The Science Behind Habit Formation and Breaking Addictive Patterns. 2025. Buabang EK, Donegan KR, Rafei P, Gillan CM. Leveraging cognitive neuroscience for making and breaking real-world habits. Trends Cogn Sci. 2025;29(1):41–59. Aguilar-Yamuza B, Trenados Y, Herruzo C, et al. A systematic review of treatment for impulsivity and compulsivity. Front Psychiatry. 2024;15. Science News Today. Why Habits Stick: The Hidden Psychology of Habit Formation. 2025.
    By Mohamad-Ali Salloum, PharmD March 30, 2026
    References: Peng Z, Jia Q, Mao J, et al. Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction . Front Psychiatry. 2024;15. 2 Walid R. The Impact of Addiction on the Brain’s Reward Circuitry, And How This Affects the Motivation and Decision-Making Processes . 2025. 3 Parra-Abarca J, Palacios-Pérez HB, Baldivia-Noyola P, et al. The relation between the dopaminergic system, drug addiction, and brain structures related to reward behaviors and decision-making . Rev Mex Neurocienc. 2025. 4 Penn LPS Online. Neuroscience and addiction: Unraveling the brain's reward system . 2025. 1 Cold Spring Harbor Laboratory. Hijacking the Brain’s Reward System: The Neuroscience Behind Addiction . 2025.
    By Mohamad-Ali Salloum, PharmD March 28, 2026
    References: Aggarwal D, Naik J, Lindquist DH. Biphasic Model of Addiction: Neurobehavioral Adaptations . Curr Behav Neurosci Rep. 2025;12:25. 1 Blithikioti C, Fried EI, Albanese E, Field M, Cristea IA. Reevaluating the brain disease model of addiction . Lancet Psychiatry. 2025;12(6):469–474. 2 Blithikioti C, Fried EI, Albanese E, Field M, Cristea IA. Reevaluating the BrainDisease Model of Addiction (Accepted Version). University of Sheffield; 2025. Unterrainer HF. Addiction, attachment, and the brain: a focused review of empirical findings and future directions . Front Hum Neurosci. 2025;19. 3 Vaswani M. Neurobiology of Addiction . Addiction Behavioral Conference 2025. Magnus Group. 
    By Mohamad-Ali Salloum, PharmD March 24, 2026
    This guide breaks down why your body reacts the way it does, how misinterpretation fuels anxiety, and the CBT tools designed to help you understand (and stop fearing) your own physical sensations.
    More Posts